After a pharma lobbying blitz, Congress softens legislation on drug patents STAT
Pharmaceutical companies appear to have succeeded in watering down legislation that would’ve made it harder for them to accumulate patents.
After a pharma lobbying blitz, Congress softens legislation on drug patents STAT
Pharmaceutical companies appear to have succeeded in watering down legislation that would’ve made it harder for them to accumulate patents.